









Markets
/
Stocks
/
nasdaq-allo
/

Allogene Therapeutics Inc

ALLO

1.690USD

+0.060+3.68%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

377.15MMarket Cap

LossP/E TTM



Allogene Therapeutics Inc

1.690

+0.060+3.68%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Allogene Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Allogene Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.38.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Allogene Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

119 / 392

Overall Ranking

254 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Allogene Therapeutics Inc Highlights

StrengthsRisks

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Growing

The company is in a growing phase, with the latest annual income totaling USD 22.00K.

Fairly Valued

The company’s latest PE is -1.73, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 141.70M shares, increasing 0.07% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 19.19K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.37.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

7.383

Target Price

+352.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Allogene Therapeutics Inc is 5.10, ranking 381 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.10

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Allogene Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Allogene Therapeutics Inc is 8.08, ranking 63 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.73, which is -54.80% below the recent high of -0.78 and -99.05% above the recent low of -3.45.

Score

Industry at a Glance

Previous score

8.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Allogene Therapeutics Inc is 8.27, ranking 144 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 14.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

8.27

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

7.383

Target Price

+352.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Allogene Therapeutics Inc

ALLO

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Allogene Therapeutics Inc is 5.85, ranking 290 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.95 and the support level at 1.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.71

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.000

Buy

RSI(14)

53.624

Neutral

STOCH(KDJ)(9,3,3)

48.592

Neutral

ATR(14)

0.167

High Vlolatility

CCI(14)

16.599

Neutral

Williams %R

53.398

Neutral

TRIX(12,20)

0.652

Sell

StochRSI(14)

18.432

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.746

Sell

MA10

1.665

Buy

MA20

1.661

Buy

MA50

1.520

Buy

MA100

1.379

Buy

MA200

1.310

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Allogene Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.47%, representing a quarter-over-quarter decrease of 4.59%. The largest institutional shareholder is The Vanguard, holding a total of 9.25M shares, representing 4.12% of shares outstanding, with 11.62% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Pfizer Inc

22.03M

TPG Capital, L.P.

18.72M

Citadel Advisors LLC

13.97M

+4.69%

BlackRock Institutional Trust Company, N.A.

11.15M

-1.42%

The Vanguard Group, Inc.

Star Investors

9.02M

+9.22%

Belldegrun (Arie S)

7.56M

PRIMECAP Management Company

Star Investors

7.08M

+23.78%

Two Sigma Investments, LP

6.19M

+81.81%

Chang (David D)

5.73M

+0.08%

Woodline Partners LP

4.36M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Allogene Therapeutics Inc is 3.70, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Allogene Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.